Activation and degranulation of basophils are often investigated to measure allergy severity, monitor acquisition of tolerance towards allergens, and observe clinical response to immunomodulatory treatments over time. Performed on whole blood samples and using flow cytometry, the basophil activation test (BAT) is an important clinical and exploratory test.
Our BAT assay will allow you to monitor the basophil population by investigating degranulation markers with a cutting-edge flow cytometry platform.
CellCarta has a long-standing expertise in deploying the BAT assay to support clinical trials. In addition to its use in the field of allergies, the BAT assay can also be used as a pharmacodynamic (PD) marker to monitor the effect of compounds targeting protein tyrosine kinases such as SYK.
At CellCarta, we use the FlowCASTTM test to investigate basophil activation in whole blood samples. Basophils are defined as SSCLOW CCR3+ and the reliable activation marker CD63 is used to investigate degranulation.